The impact of China's retail drug price control policy on hospital expenditures: A case study in two Shandong hospitals

Health Policy and Planning

Volumn 20, Issue 3, 2005, Pages 185-196

  Meng, Qingyue ^a,b,d,e   Cheng, Gang ^a   Silver, Lynn ^b,c   Sun, Xiaojie ^a   Rehnberg, Clas ^b   Tomson, Göran ^b  

^a SHANDONG UNIVERSITY   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF BRASILIA   (Brazil)

^d Department of Health Economics ^*  (China)

^e Advisory Committee of Management and Policy   (China)

Author keywords

China; Drug price; Expenditure; Hospital; Policy

Indexed keywords

ARTICLE; BRAIN INFARCTION; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL MANAGEMENT; HOSPITAL RUNNING COST; HUMAN; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY;

CHINA; DRUG COSTS; HOSPITAL COSTS; ORGANIZATIONAL CASE STUDIES; PHARMACY SERVICE, HOSPITAL; RETROSPECTIVE STUDIES;

EID: 18344380442     PISSN: 02681080     EISSN: None     Source Type: Journal    
DOI: 10.1093/heapol/czi018     Document Type: Article

References (48)

1. Adams HP Jr, Adams RJ, Brott T et al. 2003. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 34: 1056-83.
2. Adibhatla RM, Hatcher JF. 2002. Citicoline mechanisms and clinical efficacy in cerebral ischemia. Journal of Neuroscience Research 70: 133-9.
3. Bell WR. 1997. Defibronegating enzymes. Drugs 54 (Suppl 3): 18-30. discussion 30-1.
4. Berge E, Sandercock P. 2002. Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database of Systematic Reviews 4: CD003242.
5. Bloor K, Freemantle N. 1996. Lessons from international experience in controlling pharmaceutical expenditure II: influencing doctors. British Medical Journal 312: 1525-7.
6. Bossi E, Bossi L. 1989. Acute and chronic cerebrovascular diseases. A therapeutic approach. Minerva Medica 80: 991-8.
7. Capella D. 1993. Descriptive tolls and analysis. In: Dukes MNG (ed). Drug utilization studies: methods and uses. WHO Regional Publications, European Series No.45. Copenhagen: WHO Regional Office for Europe, pp. 64-5.
8. Centre for Health Statistics and Information. 1998. National Health Service Survey Report. Beijing: Ministry of Health.
9. Chen HY, Han LP, Yao XL, Ji B. 2003. Analysis of the frequency and rationality of use of antibiotics in 571 patients. China Pharmacy 14: 159-61.
10. China Health Economics Institute. 1999. Distribution of health expenditures in China. Beijing.
11. China State Commission of Planning and Development. 1998. Method of drug price management. Policy Document No. 2196. Beijing.
12. China State Commission of Planning and Development. 2000. Reforms of drug pricing policy. Document No. 961. Beijing.
13. China State Commission of Planning and Development. 2002. Analysis of decreasing index of drug prices. Price report. Beijing.
14. China State Drug Administration. 2003. National actions in reducing drug prices. Publicity Report. Beijing.
15. China State Economic and Trade Commission. 1999. Statistics of pharmaceutical industry. Beijing.
16. Chinese Pharmacy Yearbook Editing Commission. 1998. Chinese Pharmacy Yearbook. Beijing: People's Health Publishing House.
17. Cleverley W. 1992. Essentials of health care finance (third edition). Caitherburg, MD: Aspen Publishers Inc., pp. 323-7.
18. Coull BM, Williams LS, Goldstein LB et al. 2002. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 33: 1934-42.
19. Dong HJ, Bogg L, Rehnberg C, Diwan V. 1999. Drug policy in China: pharmaceutical distribution in rural areas. Social Science and Medicine 48: 777-86.
20. Du DQ. 2002. Difficulties for costing pharmaceuticals. Price Theory and Practice 3: 10-11.
21. Ess SM, Schneiweiss S, Szucs T. 2003. European healthcare policies for controlling drug expenditures. Pharmacoeconomics 21: 89-103.
22. European Stroke Initiative. 2003. Recommendations. Ischaemic stroke: prophylaxis and treatment. Accessed 1 December 2003 at: [http:// www.strokecenter.org/prof/guidelines.htm#Acute].
23. Greener J, Enderby P, Whurr R. 2001. Pharmacological treatment for aphasia following stroke. Cochrane Database of Systematic Reviews 4: CD000424.
24. Gross DJ, Kile J, Ratner J, Thomas C. 1996. Prices for prescription drugs: the role of market forces and government regulation. In: Davis P (ed). Contested ground: public purpose and private interest in the regulation of prescription drugs. New York: Oxford University Press.
25. Guo X. 2001. Use of evidence-based medicine in appraising drugs. Chinese Journal of New Drugs 10: 641-3.
26. Hu SL, Chen W, Cheng XM et al. 2001. Pharmaceutical cost-containment policy: experiences in Shanghai, China. Health Policy and Planning 16 (Suppl 2): 4-9.
27. Hu YP, Li LP. 2001. Analysis of drug cost escalation. Journal of Theory and Reform 6: 69-70.
28. Karoutas G, Milonas I, Artemis N et al. 1987. The pharmacological effects of buflomedil in patients with multi-cerebral infarcts dementia: an open, preliminary assessment. Current Medical Research and Opinion 10: 380-9.
29. Kobayashi S, Yamaguchi S, Okada K et al. 1988. Effect of long-term administration of buflomedil on regional cerebral blood flow in chronic cerebral infarction. Angiology 39: 934-41.
30. Liu H, Cheng X. 2002. Costing of community health services. Chinese General Medicine 5: 626-8.
31. Lu SQ. 2002. Why the consumers cannot enjoy the benefit after the implementation of drug price control? China Consumers 7: 44-6.
32. Maynard A, Bloor K. 2003. Dilemmas in regulation of the market for pharmaceuticals. Health Affairs 22: 31-41.
33. Meng Q, Ge R, Bian Y, Ma Y, Liu X. 1998. Analysis of fixed and variable cost in hospitals. Chinese Health Service Management 7: 383-6.
34. Meng Q, Bian Y, Ge R et al. 2002. Adjustment of health care prices for correcting the incentive structure for hospitals. Chinese Journal of Health Economics 5: 34-6.
35. Meng Q, Rehnberg C, Zhuang N et al. 2004. Impact of urban health insurance reform on hospital charges: a case study from two cities in China. Health Policy 68: 197-209.
36. Ministry of Health. 2000. Regulation of drug pricing policy for health providers. Policy Document No. 391. Beijing.
37. Ricci S, Celani MG, Cantisani AT, Righetti E. 2002. Piracetam for acute ischaemic stroke. Cochrane Database of Systematic Reviews 4: CD000419.
38. Wang Q, Wei JF. 2003. The causes of and solutions to unreasonable drug prices. Journal of Lanzhou Commercial College 19: 96-8.
39. Wei JW. 1999. Drug expenditures in China. Chinese Journal of Health Economics 22: 1-3.
40. Wu R. 1999. Cost-containment policy in China. Chinese Journal of Health Resources 2: 28-30.
41. Wu R, Yang H. 1999. Methods of containing drug expenditures in China and other countries. Chinese Primary Health Care 13: 46-7.
42. Xu L, Forbes I, Qu J et al. 2001. Assessing hospital financial reform. China-Australia Joint Research Report. Jinan City and Sydney: Shandong University and University of New South Wales.
43. Yang YH, Fu SG, Peng H et al. 1993. Abuse of antibiotics in China and its potential interference in determining the etiology of pediatric bacterial diseases. Pediatric Infectious Disease Journal 12: 986-8.
44. Yip W, Eggleston K. 2001. Provider payment reform in China: the case of hospital reimbursement in Hainan Province. Health Economics 10: 325-39.
45. Zerda A, Velasquez G, Tobar F, Vargas JE (eds). 2002. Health insurance systems and access to medicines. Geneva: World Health Organization.
46. Zhan SK, Tang SL, Guo YD, Bloom G. 1998. Drug prescribing in rural health facilities in China: implications for service quality and cost. Tropical Doctor 28: 42-8.
47. Zhang Y, Li J, Zhang X. 2000. Application of settlement in line with different diseases to the health insurance schemes. Chinese Journal of Health Economics 19: 41-2.
48. Zhao YX, Wan Q, Gao G, Du L. 2003. Health expenditures in China 2001. Chinese Journal of Health Economics 22: 1-3.